-
Someone in the OR makes a comment about a patients tattoo. In another case, a catheter doesnt get connected, and urine ends up on the OR floor. Someone gets mad about the mess and starts yelling. Do these situations sound like a bad day in the OR? Now imagine the patient wakes up in recovery and tells you she heard what your staff said, but she was paralyzed and unable to speak.
-
-
The recent withdrawal of the popular arthritis drug rofecoxib (Vioxx) from the market has left patients scrambling for alternatives and providers looking at long-term consequences.
-
New HIV guidelines address long-term management in the context of a persons overall life and health and emphasize the importance of strategies to improve adherence to drug regimens.
-
New research suggests that AIDS therapy should be initiated at higher CD4 levels than current guidelines recommend. In the study, published in the Sept. 15 issue of The Journal of Infectious Diseases, researchers wanted to reevaluate the optimal time to initiate highly active antiretroviral therapy (HAART).
-
Oral erythromycin, CYP3A inhibitor combination risky; Many patients dont tell docs about medication underuse; Scientists find potential way to control drug-resistant bacteria; Drug shortages negatively affect patient safety, costs of care.
-
New salary statistics show that hospital pharmacy administrators may make $100,000 or more and work 50 hours a week or fewer. Even so, pharmacy management positions are some of the hardest to fill, according to a second survey.
-
Physicians increasingly are aware of the need to provide prophylaxis against venous thrombosis for the medically ill patient in the hospital environment. This article attempts to separate the fact from fiction regarding VTE prophylaxis.
-
Merck announced on September 30th that it is voluntarily withdrawing rofecoxib (Vioxx) from the worldwide market.
-
Rofecoxib, celecoxib (Celebrex), and valdecoxib (Bextra) are a subclass of nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively block the enzyme COX-2 (cyclooxygenase-2). When Merck announced the rofecoxib withdrawal, it said that its study results were not necessarily applicable to others in the COX-2 inhibitor class.
